Dr Reddy's Laboratories vs Lupin: Which Stock Should You Track

Dr Reddy's Laboratories vs Lupin is a comparison investors search for because the two companies represent genuinely different positions within Pharmaceuticals. This Dr Reddy's Laboratories vs Lupin breakdown goes beyond generic labels and looks at real numbers: reach, products, the latest results each company has declared, and how each stock is positioned today. Understanding Dr Reddy's Laboratories vs Lupin this way is more useful than a surface-level label, because it shows where each company actually stands rather than how it describes itself.

Dr Reddy's Laboratories vs Lupin: Reach and Market Position

In the Dr Reddy's Laboratories vs Lupin comparison, Dr Reddy's Laboratories stands out for a Hyderabad-based global pharmaceutical major with a diversified footprint across North America, Europe, Emerging Markets and India. This scale gives Dr Reddy's Laboratories a distinct position within Pharmaceuticals that shapes how it competes.

Click Here – Get Free Investment Predictions

Lupin, on the other hand, is built around a Mumbai-based pharmaceutical company with a strong presence in respiratory, cardiovascular and anti-diabetic therapies across India, the US and other global markets. Comparing Dr Reddy's Laboratories vs Lupin on reach alone shows two different growth strategies, not a single verdict.

Dr Reddy's Laboratories vs Lupin: Key Products and Business Mix

Dr Reddy's Laboratories's business runs on generic drugs, biosimilars, active pharmaceutical ingredients, and branded formulations. This product mix is central to any Dr Reddy's Laboratories vs Lupin comparison, since it explains where each company's revenue actually comes from.

Lupin instead leans on generic and branded formulations across respiratory, cardiovascular, anti-diabetic and anti-infective therapy areas. The Dr Reddy's Laboratories vs Lupin product comparison shows these are genuinely different businesses, not just different brand names in the same category.

Dr Reddy's Laboratories vs Lupin: Latest Results

Looking at real numbers rather than claims, Dr Reddy's Laboratories's latest disclosed results show Q1 FY27 consolidated net profit of around Rs 1,290 crore, down about 8% YoY, on revenue of about Rs 7,650-8,071 crore, as North American generic sales faced pricing pressure on key molecules including lenalidomide; Emerging Markets revenue grew 31% YoY and India grew 17% YoY. This is the clearest evidence available for the Dr Reddy's Laboratories vs Lupin comparison on Dr Reddy's Laboratories's side.

Lupin's latest disclosed results show Positioned by the market among India's larger generics exporters, with growth tied to US generic approvals and India branded formulation sales. Weighing Dr Reddy's Laboratories vs Lupin on actual results, rather than headline positioning, is what separates a useful comparison from a generic one.

Compare Dr Reddy's Laboratories and Lupin Fundamentals on the Univest Screener

Dr Reddy's Laboratories vs Lupin: Stock and Valuation

On the market side, Dr Reddy's Laboratories is described as: Shares touched a 52-week low following the Q1 FY27 results per market reports. Lupin is described as: Tracked alongside Sun Pharma, Dr Reddy's, Cipla and Aurobindo Pharma as one of India's major listed pharma companies. The Dr Reddy's Laboratories vs Lupin valuation gap often reflects how the market is pricing each company's growth and risk profile differently.

Dr Reddy's Laboratories vs Lupin: Quick Comparison Table

Parameter	Dr Reddy's Laboratories	Lupin
Sector	Pharmaceuticals	Pharmaceuticals
Market position	a leading Indian pharmaceutical company with a diversified global generics and biosimilars footprint	a leading Indian pharmaceutical company in respiratory and cardiovascular generics
Reach	a Hyderabad-based global pharmaceutical major with a diversified footprint across North Am	a Mumbai-based pharmaceutical company with a strong presence in respiratory, cardiovascula
Latest results	Q1 FY27 consolidated net profit of around Rs 1,290 crore, down about 8% YoY, on revenue of about Rs	Positioned by the market among India's larger generics exporters, with growth tied to US generic app

Conclusion

Dr Reddy's Laboratories vs Lupin ultimately comes down to two companies solving similar problems in different ways. Dr Reddy's Laboratories brings a leading Indian pharmaceutical company with a diversified global generics and biosimilars footprint, while Lupin brings a leading Indian pharmaceutical company in respiratory and cardiovascular generics. Investors weighing Dr Reddy's Laboratories vs Lupin should track both companies' upcoming results and valuation gap rather than picking a side on reputation alone. This Dr Reddy's Laboratories vs Lupin breakdown is a starting point, not a final verdict.

Download the Univest iOS App or Univest Android App to track Dr Reddy's Laboratories and Lupin live price and get daily stock recommendations.

Frequently Asked Questions

What is the main difference between Dr Reddy's Laboratories and Lupin?

Ans. The main difference in the Dr Reddy's Laboratories vs Lupin comparison lies in scale and business mix. Dr Reddy's Laboratories is built on a leading Indian pharmaceutical company with a diversified global generics and biosimilars footprint, while Lupin is positioned around a leading Indian pharmaceutical company in respiratory and cardiovascular generics.

How do Dr Reddy's Laboratories and Lupin's latest results compare?

Ans. Comparing Dr Reddy's Laboratories vs Lupin on latest disclosed results: Dr Reddy's Laboratories reported Q1 FY27 consolidated net profit of around Rs 1,290 crore, down about 8% YoY, on revenue of about Rs 7,650-8,071 crore, as North American gen, while Lupin reported Positioned by the market among India's larger generics exporters, with growth tied to US generic approvals and India branded formulation sal.

What sector do Dr Reddy's Laboratories and Lupin operate in?

Ans. Dr Reddy's Laboratories operates in Pharmaceuticals and Lupin operates in Pharmaceuticals. Even where the sectors overlap, the Dr Reddy's Laboratories vs Lupin comparison shows different product mixes and market positions.

Should I invest in Dr Reddy's Laboratories or Lupin?

Ans. Both Dr Reddy's Laboratories and Lupin have distinct strengths within their space. Investors comparing Dr Reddy's Laboratories vs Lupin should review the latest quarterly results, valuation and their own risk profile, and consult a financial advisor before deciding.

What are the key products of Dr Reddy's Laboratories?

Ans. Dr Reddy's Laboratories's key products and business lines include generic drugs, biosimilars, active pharmaceutical ingredients, and branded formulations.

What are the key products of Lupin?

Ans. Lupin's key products and business lines include generic and branded formulations across respiratory, cardiovascular, anti-diabetic and anti-infective therapy areas.

How do Dr Reddy's Laboratories and Lupin compare on market position?

Ans. On market position, Dr Reddy's Laboratories holds a leading Indian pharmaceutical company with a diversified global generics and biosimilars footprint, while Lupin holds a leading Indian pharmaceutical company in respiratory and cardiovascular generics. The Dr Reddy's Laboratories vs Lupin comparison shows both companies lead in different ways rather than one being universally ahead.